⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24791229 | 0.95 | — | — | |
| SCHEMBL25911809 | 0.94 | PIK3CD (0.31) | — | |
| SCHEMBL25911681 | 0.93 | — | — | |
| SCHEMBL25911676 | 0.92 | — | — | |
| SCHEMBL24917058 | 0.92 | — | — | |
| SCHEMBL25911648 | 0.91 | CA12 (0.31) | — | |
| SCHEMBL24790481 | 0.90 | — | — | |
| SCHEMBL25911664 | 0.90 | — | — | |
| SCHEMBL24790453 | 0.90 | POLRMT (0.32) | — | |
| SCHEMBL24789416 | 0.89 | CA12 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |